Global AI in Clinical Trials Market - 2026-2033

July 2026 | 54 pages | ID: GE869895127EEN
DataM Intelligence

Abstracts

Global AI in Clinical Trials Market reached UDS 1.66 Billion in 2025 and, growing with a CAGR of 14.55% during the forecast period 2025-2035.

The Global AI in Clinical Trials Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.

A Global AI in Clinical Trials Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.

By Offering

• Software*
• Services

By Trial Phase

• Phase 1*
• Phase 2
• Phase 3

By Indication

• Oncology*
• CNS
• CVS
• Others

By End-user

• Pharmaceutical and Biotechnology Companies*
• Contract Research Organizations (CROs)
• Other End Users

Regional Analysis for Global AI in Clinical Trials Market:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

This Report Covers:

• Go-to-market Strategy.
• Neutral perspective on the market performance.
• Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
• Customized regional/country reports as per request and country level analysis.
• Potential & niche segments and regions exhibiting promising growth covered.
• Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Research Process:

Both primary and secondary data sources have been used in the global Global AI in Clinical Trials Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Contents

1. MARKET INTRODUCTION AND SCOPE

1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope

2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Offering
2.4. Snippet by Trial Phase
2.5. Snippet by Indication
2.6. Snippet by End-user
2.7. Snippet by Region

3. DYNAMICS

3.1. Impacting Factors
  3.1.1. Drivers
    3.1.1.1. Rising R&D Costs and Long Trial Timelines
    3.1.1.2. Increasing Adoption of Real-World Data & Digital Health Technologies
  3.1.2. Restraints
    3.1.2.1. Shortage of Skilled Professionals
    3.1.2.2. Limited Data Standardization and Model Transparency
  3.1.3. Opportunity
    3.1.3.1. Rising Demand for Specialized Testing Services
    3.1.3.2. Expanding Collaborations Between Tech Firms and CROs
  3.1.4. Impact Analysis

4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

4.1. Market Leaders and Pioneers
  4.1.1. Emerging Pioneers and Prominent Players
  4.1.2. Established Leaders with the Largest Marketing Brand
  4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
  4.3.1. North America
  4.3.2. Europe
  4.3.3. Asia Pacific
  4.3.4. South America
  4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Patent Analysis
4.6. Unmet Needs and Gaps
4.7. Recommended Strategies for Market Entry and Expansion
4.8. Pricing Analysis and Price Dynamics

5. AI IN CLINICAL TRIALS MARKET, BY OFFERING

5.1. Introduction
  5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Offering
  5.1.2. Market Attractiveness Index, By Offering
5.2. Software*
  5.2.1. Introduction
  5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Services

6. AI IN CLINICAL TRIALS MARKET, BY TRIAL PHASE

6.1. Introduction
  6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Trial Phase
  6.1.2. Market Attractiveness Index, By Trial Phase
6.2. Phase 1*
  6.2.1. Introduction
  6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Phase
6.4. Phase

7. AI IN CLINICAL TRIALS MARKET, BY INDICATION

7.1. Introduction
  7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  7.1.2. Market Attractiveness Index, By Indication
7.2. Oncology*
  7.2.1. Introduction
  7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. CNS
7.4. CVS
7.5. Others

8. AI IN CLINICAL TRIALS MARKET, BY END-USER

8.1. Introduction
  8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  8.1.2. Market Attractiveness Index, By End-user
8.2. Pharmaceutical and Biotechnology Companies*
  8.2.1. Introduction
  8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Contract Research Organizations (CROs)
8.4. Other End Users

9. AI IN CLINICAL TRIALS MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES

9.1. Introduction
  9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  9.1.2. Market Attractiveness Index, By Region
9.2. North America
  9.2.1. Introduction
  9.2.2. Key Region-Specific Dynamics
  9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Offering
  9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Trial Phase
  9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    9.2.7.1. U.S.
    9.2.7.2. Canada
    9.2.7.3. Mexico
9.3. Europe
  9.3.1. Introduction
  9.3.2. Key Region-Specific Dynamics
  9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Offering
  9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Trial Phase
  9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    9.3.7.1. Germany
    9.3.7.2. UK
    9.3.7.3. France
    9.3.7.4. Spain
    9.3.7.5. Italy
    9.3.7.6. Rest of Europe
9.4. Asia-Pacific
  9.4.1. Introduction
  9.4.2. Key Region-Specific Dynamics
  9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Offering
  9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Trial Phase
  9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    9.4.7.1. China
    9.4.7.2. India
    9.4.7.3. Japan
    9.4.7.4. South Korea
    9.4.7.5. Rest of Asia-Pacific
9.5. South America
  9.5.1. Introduction
  9.5.2. Key Region-Specific Dynamics
  9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Offering
  9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Trial Phase
  9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    9.5.7.1. Brazil
    9.5.7.2. Argentina
    9.5.7.3. Rest of South America
9.6. Middle East and Africa
  9.6.1. Introduction
  9.6.2. Key Region-Specific Dynamics
  9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Offering
  9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Trial Phase
  9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING

10.1. Competitive Overview and Key Market Players
10.2. Market Share Analysis and Positioning Matrix
10.3. Strategic Partnerships, Mergers & Acquisitions
10.4. Key Developments in Product Portfolios and Innovations
10.5. Company Benchmarking

11. COMPANY PROFILES

11.1. Medidata*
  11.1.1. Company Overview
  11.1.2. Product Portfolio
    11.1.2.1. Product Description
    11.1.2.2. Product Key Performance Indicators (KPIs)
  11.1.3. Financial Overview
    11.1.3.1. Company Revenue
    11.1.3.2. Geographical Revenue Shares
    11.1.3.3. Revenue Forecasts
  11.1.4. Key Developments
    11.1.4.1. Mergers & Acquisitions
    11.1.4.2. Key Product Development Activities
    11.1.4.3. Regulatory Approvals, etc.
    11.1.4.4. SWOT Analysis
11.2. IQVIA
11.3. Saama Technologies
11.4. Phesi
11.5. Euretos
11.6. Median Technologies
11.7. Innoplexus
11.8. Deep6.ai
11.9. AiCure
11.10. Antidote Technologies
11.11. Mendel AI (LIST NOT EXHAUSTIVE)

12. ASSUMPTIONS AND RESEARCH METHODOLOGY

12.1. Data Collection Methods
12.2. Data Triangulation
12.3. Forecasting Techniques
12.4. Data Verification and Validation

13. APPENDIX

13.1. About Us and Services
13.2. Contact Us